NASDAQ:RNAZ
TransCode Therapeutics, Inc. Stock News
$0.82
+0.113 (+15.98%)
At Close: May 03, 2024
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
04:15pm, Wednesday, 06'th Mar 2024
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced t
TransCode (RNAZ) Down 50% on Issue of New Common Stock
02:11pm, Friday, 19'th Jan 2024
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
Why Is TransCode Therapeutics (RNAZ) Stock Down 25% Today?
08:16am, Friday, 27'th Oct 2023
TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering. TransCode Therapeutics hasn't yet revealed details
Why Is TransCode Therapeutics (RNAZ) Stock Down 69% Today?
08:48am, Tuesday, 26'th Sep 2023
TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a press release, TransCode Therapeutics is offering 1
Transcode Therapeutic stock whipsaws lower after cut price placing
06:47am, Tuesday, 26'th Sep 2023
TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-
Why Is TransCode Therapeutics (RNAZ) Stock Up 240% Today?
01:14pm, Monday, 25'th Sep 2023
Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ ) saw its shares drive up 300% earlier this morning before settling around 240% up in the early afternoon session.
TransCode Therapeutics stock skyrockets on positive brain cancer trial results
10:38am, Monday, 25'th Sep 2023
TransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tu
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:00am, Monday, 10'th Jul 2023
TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong ag
TransCode Therapeutics to present at AACR Annual Meeting 2023
07:00am, Thursday, 06'th Apr 2023
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announc
10 Penny Stocks Under $1 To Watch Now, Time To Buy?
02:22pm, Friday, 03'rd Mar 2023
Penny stocks under $1 The post 10 Penny Stocks Under $1 To Watch Now, Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
7 Penny Stocks Under $1 To Watch Now, Time To Buy?
02:48pm, Wednesday, 01'st Mar 2023
$1 Penny stocks to watch this week. The post 7 Penny Stocks Under $1 To Watch Now, Time To Buy?
4 Penny Stocks Under $1 To Watch Now, Time To Buy?
06:40pm, Tuesday, 28'th Feb 2023
$1 Penny Stocks To Watch The post 4 Penny Stocks Under $1 To Watch Now, Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
RNAZ Stock: 4.96% This Week Explanation
10:52pm, Monday, 20'th Feb 2023
The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) increased by 4.96% this past week. This is why.
Why Is TransCode Therapeutics (RNAZ) Stock Up 45% Today?
08:03am, Wednesday, 01'st Feb 2023
TransCode Therapeutics (NASDAQ: RNAZ ) stock is rocketing higher on Wednesday following positive study results. The big news here has to do with TTX-RIGA, which is the company's immunotherapy candidat
Why Is TransCode Therapeutics (RNAZ) Stock Up 148% Today?
11:45am, Wednesday, 07'th Dec 2022
TransCode Therapeutics (NASDAQ: RNAZ ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won't pursue a plan to sell 12.5 mi